Get the Stockscreener App
11.04
2.13%
0.23
After Hours:
11.02
-0.02
-0.18%
Assembly Biosciences Inc stock is traded at $11.04, with a volume of 9,134.
It is up +2.13% in the last 24 hours and down -12.17% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$10.81
Open:
$11.02
24h Volume:
9,134
Relative Volume:
0.31
Market Cap:
$70.17M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-0.8166
EPS:
-13.5194
Net Cash Flow:
$22.49M
1W Performance:
-7.85%
1M Performance:
-12.17%
6M Performance:
-38.80%
1Y Performance:
-13.62%
1-Day Range:
$10.90
$11.41
1-Week Range:
$10.56
$11.94
52-Week Range:
$10.56
$19.93
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
11.04 | 70.17M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
ASMB stock touches 52-week low at $10.8 amid market challenges - Investing.com
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update - Defense World
Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
ASMB stock touches 52-week low at $11.44 amid market challenges - Investing.com India
ASMB stock touches 52-week low at $11.44 amid market challenges By Investing.com - Investing.com South Africa
(ASMB) Trading Report - Stock Traders Daily
Assembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trial - MSN
Assembly Biosciences Doses First Subject in Phase 1a Trial of Hepatitis Delta Virus Therapy Candidate; Shares Up - Marketscreener.com
Assembly Biosciences Initiates Phase 1a Study Of ABI-6250, Oral Entry Inhibitor For - Nasdaq
Assembly Biosciences initiates phase 1a trial for HDV treatment candidate By Investing.com - Investing.com South Africa
Assembly Biosciences initiates phase 1a trial for HDV treatment candidate - Investing.com India
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - The Manila Times
Infectious disease index recovers from -25% low, ends 2024 down 6.28% - BioWorld Online
(ASMB) Investment Analysis - Stock Traders Daily
Assembly Bio advances herpes treatment into next trial phase By Investing.com - Investing.com Nigeria
Assembly Bio advances herpes treatment into next trial phase - Investing.com
Catalent Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors - citybiz
Catalent Announces New Board Appointments - Business Wire
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes - The Manila Times
Can This New Once-Weekly Herpes Treatment Transform Patient Care? Phase 1a Results Reveal Breakthrough - StockTitan
Peapod Lane Capital LLC Takes $994,000 Position in Assembly Biosciences, Inc. (NASDAQ:ASMB) - MarketBeat
Biotechnology Market Size, Share, Trends Research Report 2025-2034 - PharmiWeb.com
JPMorgan Chase & Co. Boosts Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Reviewing Assembly Biosciences (NASDAQ:ASMB) and CytoDyn (OTCMKTS:CYDY) - Defense World
When the Price of (ASMB) Talks, People Listen - Stock Traders Daily
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
(ASMB) Technical Pivots with Risk Controls - Stock Traders Daily
Geode Capital Management LLC Has $712,000 Stock Position in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Gilead raises Assembly Bio stake to ~30% - MSN
IGM Bio stock plunges as analysts downgrade (IGMS:NASDAQ) - Seeking Alpha
ABI-4334 shows promise in hepatitis B Phase 1b trial: Data - Liver Disease News
Trend Tracker for (ASMB) - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Share Price Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Assembly Biosciences extends lease through 2029 By Investing.com - Investing.com Nigeria
Assembly Biosciences extends lease through 2029 - Investing.com India
Brokerages Set TKO Group Holdings, Inc. (NYSE:TKO) PT at $136.79 - Defense World
Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips - 24/7 Wall St.
Hedge Fund and Insider Trading News: Glenn Greenberg, Warren Buffett, Bill Ackman, D.E. Shaw, Millennium Management, Assembly Biosciences Inc (ASMB), Simon Property Group Inc (SPG), and More - Insider Monkey
Financial Analysis: Assembly Biosciences (NASDAQ:ASMB) vs. LifeVantage (NASDAQ:LFVN) - Defense World
Assembly Biosciences director Houghton buys $49,997 in stock By Investing.com - Investing.com Australia
Assembly Biosciences director Houghton buys $49,997 in stock - Investing.com India
Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Acquires $49,983.22 in Stock - MarketBeat
Gilead Buys $20.1 Million of Assembly Biosciences Stock - MSN
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Drop in Short Interest - MarketBeat
(ASMB) Long Term Investment Analysis - Stock Traders Daily
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):